Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

LeMaitre Vascular (NASDAQ:LMAT - Get Rating) is scheduled to issue its quarterly earnings data after the market closes on Thursday, July 28th. Analysts expect the company to announce earnings of $0.32 per share for the quarter. LeMaitre Vascular has set its Q2 guidance at $0.32 EPS and its FY22 guidance at $1.26 EPS.Parties that are interested in participating in the company's conference call can do so using this link.

LeMaitre Vascular (NASDAQ:LMAT - Get Rating) last posted its quarterly earnings data on Thursday, April 28th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts' consensus estimates of $0.28 by ($0.01). The company had revenue of $39.56 million during the quarter, compared to analyst estimates of $38.65 million. LeMaitre Vascular had a return on equity of 11.41% and a net margin of 17.09%. LeMaitre Vascular's revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.28 earnings per share. On average, analysts expect LeMaitre Vascular to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year. LeMaitre Vascular Price Performance

LeMaitre Vascular stock opened at $47.23 on Thursday. The stock's 50 day moving average is $44.97 and its 200 day moving average is $44.90. The firm has a market cap of $1.04 billion, a P/E ratio of 37.78 and a beta of 1.22. LeMaitre Vascular has a one year low of $38.32 and a one year high of $60.79. LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 2nd. Investors of record on Tuesday, May 17th were paid a $0.125 dividend. This represents a $0.50 dividend on an annualized basis and a dividend yield of 1.06%. The ex-dividend date was Monday, May 16th. LeMaitre Vascular's dividend payout ratio is currently 40.00%. Analyst Upgrades and Downgrades

A number of brokerages have weighed in on LMAT. StockNews.com began coverage on LeMaitre Vascular in a report on Thursday, March 31st. They issued a "hold" rating for the company. Barrington Research lowered their target price on LeMaitre Vascular from $54.00 to $50.00 in a report on Friday, April 29th.Institutional Investors Weigh In On LeMaitre Vascular

A number of hedge funds have recently added to or reduced their stakes in the business. Citigroup Inc. increased its holdings in shares of LeMaitre Vascular by 6.6% during the first quarter. Citigroup Inc. now owns 20,987 shares of the medical instruments supplier's stock valued at $975,000 after acquiring an additional 1,293 shares in the last quarter. MetLife Investment Management LLC increased its holdings in shares of LeMaitre Vascular by 58.0% during the first quarter. MetLife Investment Management LLC now owns 12,092 shares of the medical instruments supplier's stock valued at $562,000 after acquiring an additional 4,441 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of LeMaitre Vascular by 8.2% during the first quarter. Rhumbline Advisers now owns 95,806 shares of the medical instruments supplier's stock valued at $4,452,000 after acquiring an additional 7,266 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of LeMaitre Vascular by 14.1% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,567 shares of the medical instruments supplier's stock valued at $770,000 after acquiring an additional 2,042 shares in the last quarter. Finally, BlackRock Inc. increased its holdings in shares of LeMaitre Vascular by 0.9% during the first quarter. BlackRock Inc. now owns 3,175,432 shares of the medical instruments supplier's stock valued at $147,562,000 after acquiring an additional 28,008 shares in the last quarter. 84.90% of the stock is currently owned by institutional investors. About LeMaitre Vascular (Get Rating)

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.Featured ArticlesGet a free copy of the StockNews.com research report on LeMaitre Vascular (LMAT)Exxon Mobil Leads The Oil Sector: Have Both Peaked?Get These 3 Juicy Dividend Yields While They Last How Low Can DocuSign Stock Go?These 3 Mega Caps are Bear Market BuysThe Top-Rated Consumer Defensive Stocks With Yield Above 3.5% 

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider LeMaitre Vascular, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LeMaitre Vascular wasn't on the list.

While LeMaitre Vascular currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

In this episode, Kate chats with regular guest Rob Isbitts, who, as always, debunks some traditional investing ideas, such as “buy the dip” and only going long while the market is in rally mode.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.